Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J.
Leineweber CG, et al. Among authors: schebb nh.
Front Pharmacol. 2024 Jan 11;14:1354581. doi: 10.3389/fphar.2023.1354581. eCollection 2023.
Front Pharmacol. 2024.
PMID: 38273836
Free PMC article.